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background: The ovarian reserve (number and quality of oocytes) is correlated with reproductive potential as well as somatic health,
and is likely to have multiple genetic and environmental determinants. Several reproductive hormones are closely linked with the oocyte pool
and thus can serve as surrogate markers of ovarian reserve. However, we know little about the underlying genes or genetic variants.
methods: We analyzed genetic variants across the genome associated with two hormonal markers of ovarian reserve, FSH and anti-
Mullerian hormone, in a reproductively normal population of Caucasian (n ¼ 232) and African American (n ¼ 200) women, aged 25–45
years. We also examined the effects of environmental or lifestyle factors on ovarian reserve phenotypes.
results: We identified one variant approaching genome-wide significance (rs6543833; P ¼ 8.07 × 1028) and several nominal variants
nearby and within the myeloid-associated differentiation marker-like (MYADML) gene, that were associated with FSH levels in African American
women; these were validated in Caucasian women. We also discovered effects of smoking and oral contraceptive use on ovarian reserve
phenotypes, with alterations in several reproductive hormones.
conclusions: This work is the largest study on ovarian reserve in women of reproductive age and is the only genome-wide study on
ovarian reserve markers. The genes containing or near the identified variants have no known roles in ovarian biology and represent inter-
esting candidate genes for future investigations. The discovery of genetic markers may lead to better long-range predictions of declining
ovarian function, with implications for reproductive and somatic health.
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Introduction
Infertility is a significant problem in society, affecting 15% of
reproductive-aged couples (Hull et al., 1985; Menken and Larsen, 1994;
Reijo et al., 1995). Many cases of infertility appear to be the result of
defects in germ cell development that lead to reduced numbers or
quality of gametes. The quantity and quality of oocytes within the
ovaries, or ovarian reserve, are closely correlated with reproductive
potential and are likely to have multiple genetic and environmental deter-
minants. Further, ovarian reserve is affected by aging and disease, and is
closely tied to both reproductive and somatic health. Many diseases
including osteoporosis, cardiovascular disease and various cancers are
associated with loss of oocytes/follicles, ovarian dysfunction and/or the
length of the female reproductive lifespan (Cooper and Sandler, 1998;
Hartge, 2009). Hence, better prediction of both normal and aberrant
oocyte depletion would have significant clinical implications.
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Several reproductive hormones are closely correlated with the
ovarian reserve and the inevitable process of follicle depletion.
Current methods for measuring ovarian reserve and predicting age
at fertility loss and menopause include assessment of serum levels of
FSH, inhibin B and anti-Mullerian hormone (AMH), which decreases
10 years prior to menopause (van Rooij et al., 2004). AMH and
FSH are direct and indirect reflections of follicle number, respectively.
AMH is a member of the transforming growth factor-b superfamily; it
suppresses the cyclical recruitment of primordial follicles into the pool
of growing follicles and is specifically secreted by the granulosa cells of
pre-antral and antral follicles in the ovary (Durlinger et al., 2002). Thus,
AMH is present in proportion to the number of antral follicles. FSH on
the other hand, is an indirect reflection of the follicle pool; it is a
gonadotrophin secreted by the anterior pituitary in response to hypo-
thalamic release of GnRH. It stimulates follicular growth and is a key
component of the brain-pituitary-ovary axis (Gromoll and Simoni,
2005). FSH is sensitive to the inhibitory influence of inhibin
B. Inhibin B is secreted by the granulosa cells of developing and
early antral follicles. So as the number of follicles declines, so do
inhibin levels and FSH begins to rise. Thus, there is an association
between high FSH and low follicle number with ovarian aging.
Antral follicle count (AFC), transvaginal ultrasound-guided assess-
ment of follicles, is routinely performed during fertility assessments.
We have recently analyzed the correlations of several hormonal
markers and AFC with age in Caucasian women (unpublished data),
finding that only AFC and AMH parallel the decline of follicles with
age noted in histological ovarian specimens (Hansen et al., 2008). In
contrast, FSH shows an inverse relationship with AFC and follicle
number in vivo; as follicle number and AMH decline, FSH rises. It is note-
worthy that both AMH and FSH levels are highly variable among
women, even measured at the same point in the menstrual cycle.
The age of menopause has a strong heritability (Snieder et al., 1998;
de Bruin et al., 2001; Murabito et al., 2005). Ovarian aging (OVA), which
leads to menopause with the exhaustion of the follicular pool, also
seems to have a genetic component (Rosen et al., 2010a). Genetic
markers associated with ovarian reserve may have the advantage of
providing better long-range predictions of risk for declining ovarian
reserve. Thus, determining the genetic associations of rising FSH and
declining AMHmay allow for improved counseling regarding reproduct-
ive health and aging.
Most previouswork has focused onmeasuring the reproductive events
of menarche and menopause, or comparing ovarian reserve markers and
their ability to predict reproductive outcomes in the context of infertile
populations or small observational studies. Moreover, few studies have
investigated the genes or variants associated with specific reproductive
hormones. Therefore, we sought to identify genes and variants across
the genome associated with hormonal markers of ovarian reserve in a
multi-ethnic cohort recruited from the general population. We also
sought to examine the effects of environmental or lifestyle factors includ-
ing smoking and oral contraceptive use, on ovarian reserve phenotypes.
Materials and Methods
Study population
The final study population included 232 Caucasian and 200 African
American women, aged 25–45 years, who were prospectively enrolled
in a community-based cohort of the OVA Study. These women were
not seeking treatment for infertility or other medical problems. The
OVA Study comprises a multi-ethnic cohort and is focused on elucidating
clinical and genetic markers of OVA. Subjects were recruited from poten-
tially eligible female members of Kaiser Permanente (KP) Northern
California, who resided within proximity to the Women’s Health Clinical
Research Center at the University of California San Francisco (UCSF).
The socio-demographic and health-related characteristics of the KP
patient population are representative of the population of Northern Cali-
fornia (Gordon, 2006), and the final OVA participants were similar to the
KP population. Subjects were included if they were ovulatory with normal
predictable menstrual cycles of 22–35 days. Women with oligo- or ano-
vulation, surgically diagnosed endometriosis, ovarian failure (loss of all fol-
licles before the age of 40 years) or a history of uterine or ovarian
surgery were excluded. Subjects were also excluded if they had taken
oral contraceptives or medications containing estrogen or progestin
that alter the menstrual cycle within the 3 months prior to enrollment.
This work was approved by the Institutional Review Boards at KP,
UCSF and Stanford University, and informed consent was obtained for
all subjects.
Phenotypes and covariates of ovarian reserve
Blood samples were collected by venipuncture on Day 2–4 of the
menstrual cycle and used for all serum hormonal assays and genotyping.
FSH and LH levels were measured with standardized two-site chemilu-
minescence immunoassays. The intra-assay coefficients of variation
(CVs) were 1.9–2.1%, whereas the inter-assay CVs were 5.2–6.8%.
AMH was measured using a commercially available ELISA, which uses a
direct competitive immunoassay (Beckman Coulter, Marsee, France).
The AMH CVs for intra- and inter-assays were ,5.6 and ,15.3%,
respectively. Estrone (E1) and inhibin B were measured using a commer-
cially available ELISA (Diagnostic Systems Laboratories, Webster City,
TX, USA). The intra-assay CVs for E1 and inhibin B were 4.8–9.9 and
3.3–7.2%, respectively, whereas the inter-assay CVs were 7.7–13.4
and 7.8–17%, respectively. Estradiol (E2) and testosterone were mea-
sured with an automated chemiluminescent assay using the Bayer Diag-
nostics ACS:180 (Bayer Diagnostics Corp., Tarrytown, NY, USA). The
intra- and inter-assay CVs for E2 were 6.5–6.9 and 13.6–16.1%, respect-
ively. For total testosterone, the intra-assay CVs were 2.9–4.0% and the
inter-assay CVs were 6.3–6.6%.
AFCs were performed as previously described (Rosen et al., 2010b).
Briefly, all subjects underwent transvaginal ultrasound assessment of
ovarian volumes and AFC on Day 2–4 of their menstrual cycle. All follicles
with a mean diameter (of two dimensions) of 2–10 mm were counted; all
echo-free structures were regarded as follicles (Supplementary data, Fig.
S1). To eliminate experimental variability all women were examined at
the same time in their menstrual cycle, by one of two physicians, using
the same equipment, and unclear ultrasound results were excluded. Inter-
examiner concordance exceeds 90%.
All subjects completed a comprehensive questionnaire to obtain
detailed health, reproductive, lifestyle and demographic information, as
previously described (Rosen et al., 2010b). The age of each woman
was rounded off to the nearest 10th of a year. Body measurements
including weight, height and waist and hip circumference, were also
obtained. Parity or the number of children born to each woman was
also assessed. Cigarette smoke exposure was quantified from responses
to questionnaire data and categorized as ‘never, past or current’ smoker
and pack-years of smoking. Previous history of taking estrogen- and/or
progestin-containing oral contraceptive pills (OCPs) was also quantified
from questionnaire data and categorized as ‘never or past’ and total
months of OCP use.
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Genotyping and quality control
Genotypic data for the Caucasian and African American women was
obtained using the Genome-Wide Human SNP Array 6.0 (Affymetrix,
Santa Clara, CA, USA). This microarray contains more than 900 000
single nucleotide polymorphism (SNP) markers and 940 000 copy
number variant (CNV) markers; approximately one marker every 700
bases across the genome (Affymetrix, 2007). Genomic DNA was
extracted and purified from white blood cells using the QIAamp DNA
Blood Maxi Kit (Qiagen, Venlo, The Netherlands) according to the man-
ufacturer’s instructions. The DNA ligation, hybridization and microarray
scanning steps were completed according to the manufacturer’s protocols
(Affymetrix).
Stringent quality control (QC), concordance checks and SNP filtering
were employed using Genotyping Console (GTC) v.4.0 software (http://
www.affymetrix.com) to eliminate poor samples and poorly performing or
rare SNPs. The QC measures used were: QC call rate or percentage of a
specific set of 3022 control SNPs genotyped or ‘called’ in the samples
using the dynamic algorithm (filtered for QC call rate ≥86%); and contrast
QC, which is an estimate of the ability to resolve SNP signals into three
genotype clusters (filtered for contrast QC ≥0.4). Contrast QC, the
most important QC measure, uses a static set of 10 000 randomly
chosen SNPs and quantifies the difference between the highest and
lowest contrast values of the homozygote and heterozygote genotypes.
Laboratory technical QC criteria also included SNP fingerprints for
sample tracking and early detection of sample misidentification, the use
of HapMap controls to check genotype quality, gender confirmation
based on mean intensities of SNP probes on the X and Y chromosomes,
and tracking of reagent and instrument performance. In the Caucasian
group, of the final 232 samples that passed QC and filter criteria, the
mean contrast QC was 1.87+ 0.046, the QC call rate was 93.9+
0.2% and the overall sample call rate was 98.0+0.08%. In the African
American group, of the final 200 samples, the mean contrast QC was
2.23+ 0.036, the QC call rate was 97.0+0.1% and the overall sample
call rate was 99.4+ 0.08%. SNPs were genotyped using GTC v.4.0,
using the Birdseed v.2.0 algorithm (Korn et al., 2008), which is an exten-
sion of the Bayesian Robust Linear Model with Mahalanobis Distance using
perfect-match probes. Clustering analysis and examination of relative
sample intensity, as well as filtering for high sample call rates (≥95%)
ensured high sample quality prior to downstream association analysis. Indi-
vidual SNPs across the genome were filtered for SNP call rates .95%,
missing call rates ,5%, minor allele frequency (MAF) .1% and lack of
significant deviation from Hardy–Weinberg equilibrium (P. 0.007). Of
909 622 SNP probes on the array, 677 261 and 738 185 in the Caucasian
and African American cohorts, respectively, passed QC and SNP filter
criteria and were independently tested for association with FSH and
AMH. Using the 940 000 CNV probes on the array, future investigations
will examine CNVs across the genome and their association with hormo-
nal and clinical markers of ovarian reserve. All SNP locations are refer-
enced to National Center for Biotechnology Information (NCBI) human
genome build 37 (February 2009) and dbSNP build 131 (April 2010)
(http://www.ncbi.nlm.nih.gov/projects/SNP). Gene names provided in
all tables and text represent the HUGO Gene Nomenclature Committee
(HGNC) gene symbols of the gene containing, or closest to, the identified
SNP (http://www.genenames.org/).
Determination of population structure
For ethnicity validation and tests of population structure a principal
component analysis (PCA) using singular value decomposition (svd) was
performed. Subjects of the HapMap CEU (Utah residents with N. and
W. European ancestry from the CEPH collection) and YRI (Yoruban in
Ibadan, Nigeria) cohorts were genotyped using the same genotyping
platform (http://hapmap.ncbi.nlm.nih.gov/) (International HapMap
Consortium, 2005). The OVA cohorts were combined with the
HapMap CEU and YRI cohorts, and missing genotypes were imputed
using the program BEAGLE v.3.0.2 (http://www.stat.aukland.ac.nz/
~bbrowning/beagle/beagle) (Browning, 2006; Browning and Browning,
2007). Genotypes at 10 000 SNPs, selected to have low levels of linkage
disequilibrium (LD) and MAF .0.01, distributed across several chromo-
somes were coded as 0, 1 or 2 (AA, AB and BB) and were mean-
centered. PCA was performed using the ‘svd’ function of the statistical
program R v.2.11.1 (http://www.r-project.org/) (Gentleman and Ihaka,
2008) to analyze allele composition and population homogeneity (Supple-
mentary data, Fig. S2).
Statistical analysis
Phenotypic and covariate analysis
Descriptive statistics were calculated for all hormonal, environmental and
demographic variables in the study cohorts. The relationship between
hormonal variables, follicle number and age was analyzed in linear regres-
sion analyses. For binary variables including smoking and OCP use, linear
regressions of the hormone concentration versus age were compared
between women that currently or previously smoked or used OCPs,
and those that did not. Statistical differences between the slopes and inter-
cepts of the regressions were analyzed using the F-test for variable inclu-
sion with subject age mean-centered. P, 0.05 was considered statistically
significant. Three models with different effects of smoking (or OCP use)
were tested against the simple null model of an association between the
hormone alone (hormone  Age). The three models tested were: (1)
smoking changes the intercept (hormone  Age + Smoking); (2) the
slope (hormone  Age + Smoking × Age) or (3) both slope and intercept
(hormone  Age + Smoking + Smoking × Age). For these analyses,
women that previously smoked were grouped with smoking women, as
we reasoned if a woman ever smoked, there may have been irreversible
effects on her ovarian reserve. Similar analyses were performed on the
associations between follicle number and smoking or OCP use. Pack-years
of smoking and total months of OCP use were also analyzed for their
association with serum hormone levels, with control for age. Outliers
were removed based on sensitivity analyses. Mean total serum hormone
levels or AFCs were also compared between smoking (or OCP-using)
and non-smoking (or non-OCP-using) women, using the Student’s t-test
or Welch 2-Sample t-test within R v.2.11.1 (Gentleman and Ihaka,
2008). Covariates, including smoking, OCP use and follicle number, that
were significantly associated with FSH or AMH were also controlled for
in downstream genome-wide association (GWA) analyses.
SNP association analysis
GWA analyses were performed in the context of a robust regression of
FSH or AMH versus age using the application quantreg v.4.44 (Koenker,
2009) within R.A. Fisher’s exact test for single-marker (SNP) and multiple-
marker (haplotype) association using the allelic test was performed to
determine associations with serum hormone levels using BEAGLE
v.3.0.2 and quantreg v.4.44; both programs were integrated in
R v.2.11.1. The effect sizes or the difference in the mean hormone level
from the overall regression fit, by allele or genotype were calculated for
all SNPs. In parallel validation analyses, allelic and genotypic tests using
the Kruskal–Wallace rank-sum test determined SNPs significantly asso-
ciated with FSH or AMH, as quantitative variables. For each SNP allele
and genotype, a linear regression fit of FSH or AMH versus age was
obtained, the residual was computed for each woman, and the women
were ranked into groups based on the allele/genotype to determine
whether one allele/genotype had higher or lower residuals (effect sizes)
than expected by random chance alone. Associations determined by the
596 Schuh-Huerta et al.
Fisher’s exact test were also significant as determined by the Kruskal–
Wallace test, for all top hits.
LD of variants, the number of SNPs involved in the association signals,
the genes and the recombination rates of the regions surrounding the top
hits were analyzed within BEAGLE, Haploview v.4.2 (http://www.
broadinstitute.org/mpg/haploview) (Barrett et al., 2005) and LocusZoom
v.1.1 (http://csg.sph.umich.edu/locuszoom/) (Pruim et al., 2010). LD
tagging was performed with the Tagger program (de Bakker et al., 2005)
within Haploview to capture SNPs with squared correlation coefficients
of R2 ≥ 0.8 and LD of flanking SNPs was similarly analyzed within
LocusZoom.
To verify associations and determine final significance levels, permuta-
tion testing (1000 tests) was performed and P, 0.05 were selected for
at the chromosome-wide level. Bonferonni correction for multiple
testing and family-wise errors rates were computed to verify significant
associations at the genome-wide level. P-values were computed and ana-
lyzed at both the chromosome- and genome-wide-levels, owing to our
sample size/power constraints. Further, as several chromosomes have
loci associated with ovarian reserve and function, variants were also ana-
lyzed specifically at the chromosome level. Although accepted genome-
wide significance thresholds are typically 5 × 1028, because of our
marginal sample size (which is large for a clinical/biological study but
moderate for a GWA study), assuming a slightly higher genome-wide
threshold of P, 1 × 1027, we note that the top hit identified in this
study is at a marginal genome-wide significance level. Custom-made pro-
grams and algorithms were used to mediate streamlined analyses and visu-
alization of results within R.
Results
Genetic association analysis
As shown in Table I, in 232 Caucasian and 200 African American
women, the average FSH levels were 7.1+ 0.2 and 7.4+0.3 IU/l,
respectively. The mean AMH level was 30.1+1.5 pM in Caucasians
and 22.8+1.7 pM in African Americans, with a significant difference
between the two racial groups (P, 0.001). Both hormones were cor-
related with female age (Fig. 1) and follicle number (P, 0.05). In
Caucasian women, FSH had an extrapolated rate of increase of
0.27 IU/l per year of female age (Fig. 1A). In African American
women, similar relationships were observed, with a rise of
0.16 IU/l of FSH per year of female age (Fig. 1A). AMH was most
closely correlated with both female age (Caucasians: R2 ¼ 0.22;
African Americans: R2 ¼ 0.043) and follicle number (Caucasians:
R2 ¼ 0.67; African Americans: R2 ¼ 0.36; P, 0.05); AMH decreased
with increasing age and declining AFCs. In Caucasian women, AMH
decreased 2 pM per year, while in African American women it
decreased 0.84 pM per year (Fig. 1B). Both FSH and AMH levels
were less strongly correlated with age in the African American popula-
tion, compared with the Caucasian population (FSH: R2 ¼ 0.06 versus
0.15; AMH: R2 ¼ 0.04 versus 0.22, respectively). FSH and AMH levels
were more variable among African American women and higher follicle
numbers were not always predictive of higher AMH levels.
As two good hormonal markers of ovarian reserve, FSH and AMH
were independently analyzed for associations across the genome.
Figure 2 shows the GWA results for FSH in African American
(Fig. 2A and B) and Caucasian (Fig. 2C and D) women. Figure 3
depicts the genome-wide results for AMH. In the African American
cohort, the top three genetic loci associated with FSH levels localized
to chromosomes 2 and 10 (Fig. 2B and Table II). Notably, one
marginally genome-wide significant SNP (rs6543833) was associated
with FSH in the African American population (P ¼ 8.07 × 1028).
This variant, at 2p22.3, is located just upstream of the
myeloid-associated differentiation marker-like (MYADML) gene and was
associated with a mean increase of 1.0+ 0.2 IU/l and a decrease of
0.6+ 0.3 IU/l FSH for the CC and GG genotypes, respectively
(MAF ¼ 0.27; Table II and Fig. 4A). The next most significant SNP,
rs12465811, at the same loci on chromosome 2, was also associated
with FSH (P ¼ 4.28 × 1027; MAF ¼ 0.32). This variant was associated
with an increase of 1.0+0.2 IU/l and a decrease of 0.4+0.2 IU/l
FSH for the GG and TT genotypes, respectively (Table II and
Fig. 4A). Regional association analyses of the 800 kb surrounding
these loci indicated that these variants were in LD and several
nearby SNPs were involved in the association signal (Fig. 2E). The
third nominally associated variant rs11255291, localized to 10p14,
upstream of the inter-alpha (globulin) inhibitor H2 (ITIH2) gene and
was associated with a decrease of 1.3+ 0.2 IU/l and an increase of
1.2+ 0.4 IU/l FSH for the TT and CC genotypes, respectively
(Table II).
In the Caucasian cohort, the top three genetic loci associated with
FSH localized to chromosomes 12, 5 and 11 (Fig. 2C and D). As sum-
marized in Table II, the two most significant SNPs in the Caucasian
women, rs6488619 and rs10061804, were nominally associated with
FSH (P ¼ 9.43 × 1027 and 1.47 × 1026; MAFs ¼ 0.25 and 0.28)
and localized to 12p13.1 and 5p13.3, respectively.
............................... ...............................
........................................................................................
Table I Variables of the study population.
Caucasians African Americans
Mean+ SEM n Mean+ SEM n
Age (years) 35.3+0.3 232 35.6+0.4 200
FSH (IU/l) 7.1+0.2 232 7.4+0.3 200
AMH (pM) 30.1+1.5* 232 22.8+1.7* 200
LH (IU/l) 5.8+0.2* 232 4.5+0.2* 200
Inhibin B
(pg/ml)
54.9+1.9* 232 44.4+2.4* 200
Estradiol
(pg/ml)
48.3+3.6 232 45.7+1.7 200
Estrone
(pg/ml)
61.7+1.6 232 63.3+1.6 200
Total
testosterone
(ng/dl)
52.9+1.0* 232 45.3+1.0* 200
Past/current
smokersa
45.5% (15.9+1.0) 106 23.3% (14.3+1.4) 47
Non-smokersa 54.5% (14.9+0.7) 127 76.6% (16.0+0.9) 154
OCP usersa 79% (14.9+0.6) 195 72% (14.3+0.8) 145
Non-OCP
usersa
21% (17.2+1.3) 48 28% (18.9+1.6) 56
Values are shown as mean+ SEM or percentage of the cohort.
AMH, anti-Mullerian hormone; OCP, oral contraceptive pill.
aParentheses denote AFC values (mean+ SEM).
*Significant differences between Caucasian and African American women
(P, 0.001).
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Variant rs6488619, is located within an intron of the glutamate recep-
tor, ionotropic, N-methyl D-aspartate 2B (GRIN2B) gene and led to a
mean decrease of 1.1+ 0.4 IU/l and an increase of 1.2+ 0.3 IU/l
FSH for the CC and TT genotypes, respectively. Analysis of the sur-
rounding region indicated that several variants at this loci were asso-
ciated with FSH and a few of these were in LD (Supplementary
data, Fig. S3A). Variant rs10061804 on chromosome 5 is located
within an intron of the natriuretic peptide receptor C/guanylate cyclase
C (NPR3) gene and was associated with increases of 2.1+0.8 and
1.1+ 0.4 IU/l FSH for the TT and CT genotypes, respectively.
There were several SNPs in close proximity at the 5p13.3 region
that approached chromosome-level significance (see Fig. 2B). The
last SNP, rs4944804 at 11q13.4, weakly associated with FSH, is
located immediately upstream of the ATG autophagy related 16-like 2
(Saccharomyces cerevisiae) (ATG16) gene and was associated with an
increase of 1.2+ 0.4 IU/l FSH for the GG genotype.
There were fewer genetic variants associated with AMH compared
with FSH, in both Caucasian and African American women. In the
African American cohort, weakly associated variants localized to
3p25.1 and 11p15.1 near or within the tetra-peptide repeat homeobox-
like (TPRXL) and transmembrane protein 86A (TMEM86A) genes,
respectively (Table III and Fig. 3A and B). The top genetic loci in
the Caucasian cohort were located on chromosome 6, with only
very weakly associated variants on chromosomes 18, 4 and 13
(Fig. 3C and D). The most significant SNP rs12213875, which was
nominally associated with AMH (P ¼ 2.96 × 1027; MAF ¼ 0.37) loca-
lized to 6p23 and is upstream of the Jumonji, AT rich interactive domain 2
(JARID2) gene. This variant was associated with a mean increase of
13.8+4.2 pM, an increase of 9.9+2.1 pM and a decrease of
1.3+ 1.4 pM AMH for the AA, AG and GG genotypes, respectively
(Table III and Fig. 4B). Several variants adjacent to the top SNP asso-
ciated with AMH in both ethnic groups showed some degree of LD
and many variants in these regions were associated with the signals
(Supplementary data, Fig. S4). Many other SNPs were only weakly
associated with AMH levels and are located within or near
the thioredoxin-related transmembrane protein 3 (TMX3), inositol
polyphosphate-4-phosphatase, type II (INPP4B) and WAS protein family,
member 3 (WASF3) genes. Interestingly, several variants associated
with FSH or AMH (this study), or AFC (previous unpublished
work), localized to the same genomic regions of 12p13.1–13.2 and
13q12.13.
In replication studies, the top variants associated with FSH were
examined in the Caucasian population as an independent replication
cohort. The top SNP rs6543833, had a P-value of 0.012 with an
MAF of 0.32, while the next most significant SNP rs12465811, had
a P-value of 0.071 with an MAF of 0.33 (Supplementary data, Table
S1). When only controlling for these two tests, the top SNP was
significant in the replication cohort at a P, 0.05 level. As shown in
Supplementary data, Table S1, the 300 SNPs flanking this variant
were also examined and it was discovered that nine adjacent SNPs
had relatively low P-values of 1.5 × 1023 to 7.2 × 1023. The regional
plots of these variants and their association signals are also indicated in
Supplementary data, Fig. S3B. Comparing the expected versus the
observed numbers of SNPs in this region with these low P-values indi-
cates that this cluster of SNPs was unlikely the result of random
chance. There were three times as many SNPs with low P-values
than expected based on observed P-value distributions. These findings
provide confirmation of the top SNP as well as other associated loci in
the surrounding region. Interestingly, all of these variants occurred
within or upstream of the MYADML gene, which may represent an
Figure 1 Measurements of FSH and AMH versus age in women of the entire study population. Total serum concentrations of FSH and female age in
Caucasian and African American women indicate that FSH increases with age in both ethnic groups (A). Total serum concentrations of AMH versus
age indicate that AMH decreases with age but is highly variable between women and is more variable among African American women (B). The
corresponding correlation coefficients (R2) and linear equations are shown (n ¼ 200–232 women).
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excellent candidate gene for future studies in women of both
European and African ancestry. Replication of these findings in inde-
pendent cohorts of reproductive-aged women and meta-analyses in
larger combined GWA studies are needed.
In an attempt to further examine the genetic variants associated
with FSH and AMH, we tested the top hits for association with
another well-known marker of ovarian reserve—AFC. A total of
four and five SNPs associated with FSH or AMH levels in Caucasian
or African American women, respectively, were tested for association
with AFC. Final P-values were corrected for the number of tests and
considered significant at a level of P, 0.05. Effect sizes in terms of
direction (higher or lower FSH/AMH levels or AFCs) and magnitude
(total differences in the mean hormone concentration or mean
number of follicles from the overall regression fit) for the effect
Figure 2 Summary of GWA results for FSH by chromosome showing Manhattan plots of the uncorrected (A and C) and corrected (B and D)
P-values of the Fisher’s exact test in the African American (A and B) and Caucasian (C and D) populations. Each point represents a SNP from the single
SNPs and haplotype tests of association remaining after QC and SNP filtering (677 261 in the Caucasian cohort and 738 185 in the African American
cohort). The red dashed lines indicate P-values of 1.5 × 1026 (uncorrected) and 0.05 (corrected), chromosome-wide significance level. (E) Regional
association analyses of 800 kb (272 SNPs) flanking the top variant associated with FSH in the African American cohort (rs6543833), including the
number of SNPs involved in the signal, their P-values, the LD among these variants, genes in the region and the recombination rates (hg build 18,
HapMap Phase II CEU reference, legend showing LD).
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allele/genotype were compared for all variants tested. Interestingly, as
shown in Table IV several variants associated with FSH or AMH were
also associated with the number of antral follicles. The most significant
variant, rs6543833, was associated with a decrease of 0.62+
0.34 IU/l FSH and an increase of 1.09+ 0.32 antral follicles for the
GG genotype (P ¼ 9.25 × 1023). Variant rs9875589 associated with
AMH in African Americans, had the strongest association with follicle
count; the effect allele, C, led to an increase of 14.02+ 3.72 pM AMH
and a corresponding increase of 4.88+0.63 follicles (P ¼ 1.84 ×
1024). Notably, in almost all cases the magnitudes and directions of
effects were as expected, with variants associated with lower FSH
levels correlated with higher follicle counts and variants associated
with higher AMH levels correlated with higher follicle counts. Control-
ling for follicle number in the GWA of FSH/AMH did not affect the
top associations. Further, there were both shared and independent
associations between the hormonal markers and follicle number, indi-
cating that both of these traits are independently associated with
distinct genetic variants and are significant markers of ovarian reserve.
Phenotypes and covariates of ovarian reserve
Serum levels of various circulating hormones potentially related to
ovarian function and OVA were measured as shown in Table I. The
means and ranges of hormone levels were within the spectrum of
normal variation. There were significant differences between the
hormone profiles of the two racial groups, with pronounced
differences in AMH (P ¼ 0.00074), LH (P ¼ 2.28 × 1025), inhibin B
(P ¼ 0.00049) and testosterone (P ¼ 0.00041). All of these hormones
were significantly lower in the African American women. The associa-
tions between environmental variables including smoking and OCP
use, and ovarian reserve markers were also analyzed. Among the
Caucasian population, 45.5% were either current or previous
smokers (14.6 current and 30.9% previous smokers) with an overall
average of 9.6+ 0.6 years of smoking and a range of 1–25 years.
Fewer African Americans were current or previous smokers with
only 23.3% being current (11.4%) or previous (11.9%) smokers,
with an overall average of 9.8+1.2 years of smoking and a range of
1–27 years. There was no significant difference between the mean
AFCs of women that were current or previous smokers versus that
of non-smokers in the Caucasian cohort (P ¼ 0.36) nor in the
African American cohort (P ¼ 0.34). In the Caucasian population,
when controlling for age there was no correlation between the total
pack-years of smoking and follicle number (R2 ¼ 20.057, P . 0.05).
However, there was a trend for decreased follicle numbers among
the smoking versus non-smoking African American women (14.3+
1.4 versus 16.0+0.9, respectively). Although, owing to the small
number of African American smokers further comparisons were not
feasible.
As shown in Fig. 5, the circulating serum levels of several reproduct-
ive and sex steroid hormones were significantly different between
Figure 3 Summary of GWA results for AMH by chromosome showing Manhattan plots of the uncorrected (A and C) and corrected (B and D)
P-values of the Fisher’s exact test in the African American (A and B) and Caucasian (C and D) populations. Each point represents a SNP from the single
SNPs and haplotype tests of association remaining after QC and SNP filtering (677 261 in the Caucasian cohort and 738 185 in the African American
cohort). The red dashed lines indicate P-values of 1.5 × 1026 (uncorrected) and 0.05 (corrected), chromosome-wide significance level.
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smoking and non-smoking Caucasian women. Testosterone levels
were 56+1.6 versus 50.3+ 1.2 ng/dl (P ¼ 0.0035), AMH levels
were 33.5+ 2.4 versus 27.4+1.7 pM (P ¼ 0.038) and E1
levels were 65.2+2.8 versus 58.8+ 1.7 pg/ml (P ¼ 0.043), among
smoking and non-smoking women, respectively (Fig. 5G). The regres-
sion fit of these and other hormones with female age was also signifi-
cantly different between smoking and non-smoking women, with the
most pronounced differences in E2 and testosterone levels (P ¼
0.0045 and 0.0053, respectively; Fig. 5E and F). The regression of
AFC versus age was also significantly different between smoking and
non-smoking women, with a greater extrapolated rate of follicle
decline among smoking women (P ¼ 0.039; Fig. 5A).
Seventy-nine percent of the Caucasian women and 72% of the
African American women had previously used OCPs. Total months
of use were 63.0+4.2 (range ¼ 1–216 months) in the Caucasian
population and 56.0+ 5.4 (range ¼ 1–264 months) in the African
American population. In the Caucasian women, there were no statis-
tically significant differences between the mean serum hormone levels
or AFCs of women who previously took OCPs versus those who did
not (P. 0.05). There was also no dose–response or association
between the total number of months of OCP use and the total
number of follicles (R2 ¼ 0.014 and 1 × 1026 in Caucasians and
African Americans, respectively). In contrast, in the African American
population there was a significant increase in the number of follicles in
women who had never taken OCPs (P ¼ 0.0046; Fig. 5H). In both
ethnic groups, there were trends for increased follicle numbers in
women who had never taken OCPs compared with those who had
(Caucasians: 17.2+1.3 versus 14.8+0.6, respectively, P ¼ 0.058;
African Americans: 18.9+ 1.6 versus 14.3+ 0.8, P ¼ 0.0046;
Fig. 5H). There were similar trends with several reproductive hor-
mones and AFC regressed on age, between previous OCP-users
and non-OCP-users (Supplementary data, Fig. S5). Despite the
effects of smoking and OCP use on ovarian reserve phenotypes,
adjusting for them in linear regression analyses did not affect the
genetic associations. This indicates that the effect of each variant
likely occurs directly on ovarian reserve/hormone levels, rather than
through one of these covariates.
Discussion
Genetic variants associated with FSH
and AMH
As FSH and AMH are two established clinical markers of ovarian
reserve and are closely associated with the number of antral follicles
within the ovaries, we aimed to determine whether they might be
associated with underlying genetic loci. Identification of these loci
could provide markers and long-range predictors of poor ovarian
reserve and infertility. Here, we used a genome-wide approach to
analyze genetic variants associated with these reproductive hor-
mones, as surrogate measures of ovarian reserve in a multi-ethnic
fertile population of women. We identified 1 SNP, rs6543833,
approaching genome-wide significance at P ¼ 8.07 × 1028 and
several nominal SNPs associated with FSH levels in African American
and Caucasian women, respectively, whereas, only nominally signifi-
cant variants were associated with AMH levels. In validation
studies, the top hit associated with FSH was significant in the
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other ethnic cohort (Caucasians). Additionally, there were nine adja-
cent SNPs in the nearby upstream region with significantly low
P-values, and all were within or near the MYADML gene. We also
found that several top hits associated with FSH or AMH were also
significantly associated with follicle number, with similar magnitudes
and directions of effects. These results provide validation of the asso-
ciation and evidence for underlying genetic associations between
these three phenotypes, as well as their ability to serve as independ-
ent but also overlapping ovarian reserve markers. Moreover, several
variants associated with AMH or FSH (this study), and follicle count
(unpublished data), localized to the same genomic regions of
12p13.1–13.2 and 13q12.13, which may be a hot spot for causative
alleles linked with ovarian reserve.
None of the variants were within or close to known ovarian genes
and therefore identify excellent candidate genes for further investiga-
tions. While these findings are interesting and the largest study to
date on genetic markers of FSH and AMH, future meta-analyses and
additional validation in independent studies are needed. To our knowl-
edge, this is the only study to genotype and examine ovarian reserve
hormones in a fertile population of women. All previous cohort
studies that have analyzed some aspect of ovarian reserve have utilized
either post-menopausal women (over age 45 years) or women
recruited through infertility/reproductive clinics and are therefore
not reproductively ‘normal’ populations. This work is the first to
analyze a cohort of women (non-menopausal) of reproductive age
recruited from the general population and not seeking infertility
treatments. This study is also the first to examine these reproductive
traits in women of African as well as European ancestry, and may help
to provide a baseline and foundation for future study of these ethnic
groups.
As indicated by our previous work in a larger population of 245
Caucasian women, and validated here in both Caucasians and
African Americans, of all hormonal, anthropometric and environmen-
tal variables, AMH and FSH were most closely associated with female
age and follicle number. AMH paralleled the pattern observed
between follicle number and age both in vivo and in histologic
ovarian specimens (Hansen et al., 2008), while FSH was inversely
related. Consistent with the role of AMH, we found that in Caucasian
and African American women AMH and follicle number were closely
related and both declined with female age. Interestingly, AMH levels
were more variable among African American women compared
with Caucasian women, and showed a weaker correlation with age.
As predicted, FSH levels increased with both female age and decreas-
ing follicle number in both ethnic groups, and surprisingly, were also
more variable and less strongly correlated with age among African
American than Caucasian women. It is interesting to note that none
of the subjects had polycystic ovary syndrome or other reproductive
disorders, which could be associated with elevated AMH or FSH
levels. All women also had regular cycles and no hyperandrogenemia.
Therefore, the greater variability cannot be explained by ovarian or
other hormonal disorders. To our knowledge there is no other
study with which to compare these results and no other study to
Figure 4 Phenotypes and genotypes of SNPs associated with FSH and AMH. Shown are scatter plots depicting high (H) and low (L) FSH and AMH
by age in African American (A) and Caucasian (B) women. Shown is the distribution of genotypes among the women with respect to age and FSH or
AMH for the most significant variants: (a) rs6543833 and (b) rs12465811 (for FSH) and (c) rs12213875 (for AMH). The three genotypes are desig-
nated by blue, orange and red points (n ¼ 200–232 women).
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assess these hormones in normal fertile women of African and Euro-
pean ancestry.
Several hormones, including FSH, AMH, E2 and inhibin B, among
others, have been correlated with ovarian response to controlled
ovarian stimulation or pregnancy outcomes in IVF cycles (Eldar-Geva
et al., 2005; Wunder et al., 2008; Wu et al., 2009). Studies have
reported that AMH may be the best marker of ovarian reserve as it
can be measured throughout the menstrual cycle and is more
closely associated with the number of oocytes retrieved and repro-
ductive outcomes in IVF (Durlinger et al., 2002; Wunder et al.,
2008; Wu et al., 2009). AMH also has a reported lower variability
within and between cycles in the same women (van Disseldorp
et al., 2010). Previous work has also identified a few variants in the
genes encoding the receptors for AMH and FSH, AMHR2 (Kevenaar
et al., 2007) and FSHR (Gromoll and Simoni, 2005; Loutradis et al.,
2006), and found correlations with various reproductive parameters
including age at menopause, or FSH sensitivity and menstrual cycle
length, respectively. Interestingly, a recent large-scale candidate gene
association study found that the group of genes involved with
steroid hormone metabolism and biosynthesis pathways including
FSHB, was significantly associated with age of menopause (He et al.,
2010). This indicates that several reproductive (i.e. FSH) and sex
steroid hormones may share underlying genetic associations that are
linked with the reproductive lifespan. However, many of these
studies relied on comparisons of hormone profiles and their ability
to predict reproductive outcomes in the context of small populations
of infertile or subfertile (or post-menopausal) women. Thus, we now
identify genetic variants associated with markers of ovarian reserve in
a large community-based population.
None of the genes associated with the identified variants have
demonstrated roles in ovarian biology and are therefore interesting
candidate genes. As FSH and AMH are related to ovarian function
and reflective of ovarian reserve, the genes and variants associated
with them might have roles in the brain-pituitary-ovary axis and be
expressed within the ovary or brain—and some of them are. The
two top variants, as well as other nearby variants associated with
FSH are located upstream or within the MYADML gene at 2p22.3.
MYADML has almost exclusive expression in the human testis and
limited expression in the brain (www.ncbi.nlm.nih.gov/unigene).
However, the role of this gene in ovarian biology is unknown. The
GRIN2B gene containing the top SNP at 12p13.1 associated with
FSH in Caucasian women, encodes one subunit of the ionotropic
NMDA glutamate receptor, which is involved in learning and
memory and expressed within the brain and testis. Genetic association
studies have implicated this gene in several neurological diseases (Allen
et al., 2008), however studies of this receptor in ovarian function are
lacking. The two variants marginally associated with AMH in Caucasian
women are located upstream of the JARID2 gene at 6p23. JARID2 is an
ortholog of the mouse jumonji gene, which encodes a DNA-binding
nuclear protein and regulator of histone methyltransferases that is
essential for embryogenesis and differentiation. JARID2 negatively reg-
ulates cell growth and proliferation and is ubiquitously expressed, with
expression in both human and mouse oocytes and ovary, and human
embryonic stem cells (Ovarian Kaleidoscope: http://ovary.stanford.
edu/) (Ben-Shlomo et al., 2002). Therefore, JARID2 could play a
role in germ cell and/or somatic cell growth within the developing
ovary.
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Interestingly, several variants associated with FSH or AMH were
also associated with AFC and variants associated with all three
ovarian reserve markers localized to some of the same genomic
regions. A variant associated with AMH (rs17084228) and a variant
associated with AFC, were located within the same 30-kb genomic
region of 13q12.13, where the nearest genes are GPR12 and
WASF3. Both genes are predominantly expressed in the brain, with
WASF3 also highly expressed in the ovary. One SNP associated with
FSH (rs6488619), and two other SNPs associated with AFC, were
also located in a similar genomic region at 12p13.1 and 12p13.2,
respectively. Therefore, these genomic regions on chromosomes 12
and 13, which also comprised long stretches of associated SNPs in
LD, may be hot spots for causative alleles or genes associated with
ovarian reserve. Further, as all of these ovarian reserve markers had
both distinct and shared genetic loci, this emphasizes the multi-
factorial and polygenic nature of ovarian reserve and female fertility.
Future functional studies may examine the expression of these genes
in human ovarian tissue and female germ cells, altered gene expression
in ovarian tissue from women with different genotypes, and genetic
over-expression and silencing studies in ovarian and stem cell lines.
This work will help to elucidate the expression patterns and functional
roles of these candidate genes in human ovarian biology.
Environmental factors associated with
ovarian reserve
Environmental factors can affect human reproductive traits. We dis-
covered modest effects of smoking and OCP use on clinical markers
of ovarian reserve, with alterations in several reproductive and sex
steroid hormones, as well as follicle numbers. Smoking has adverse
effects on fertility and pregnancy. There is continuing debate about
the relationship between cigarette smoke and ovarian failure. Studies
have reported an association between smoking and an earlier age at
natural menopause, with women who smoke entering menopause
1–2 years earlier than comparable non-smokers (Torgerson et al.,
1994; Bromberger et al., 1997; van Noord et al., 1997; Cooper
et al., 1999; Gold et al., 2001). Former smokers also reportedly
have a slightly earlier age of menopause than non-smokers (Willett
et al., 1983; Cooper et al., 1999) and women prenatally exposed to
maternal cigarette smoke may enter menopause sooner (Strohsnitter
et al., 2008). Limited studies on special patient/infertility populations
have suggested that smoking is not associated with AFC or AMH
levels (Kinney et al., 2007; Nardo et al., 2007) but is associated with
elevated FSH levels (Kinney et al., 2007).
It is plausible that tobacco toxins have detrimental effects on the
follicular pool and increase rates of follicular atrophy and atresia,
leading to lower AFCs, alterations in ovarian reserve hormones, and
ultimately, reduced fertility and an earlier menopause. We found
that smoking was associated with increased serum levels of testoster-
one, E1, E2, AMH and a trend for increased FSH levels. This under-
scores the potential effects of smoking on the ovarian reserve and
suggests that smoking may alter steroidogenesis, OVA and/or the
hypothalamic-pituitary-ovarian axis. Indeed, previous work has found
that levels of sex steroid hormones, such as testosterone, are signifi-
cantly elevated in smokers (Deslypere and Vermeulen, 1984; Dai
et al., 1988), while other studies have reported alterations in sex
steroids including lower concentrations of E1, E2 and estriol (Soldin
et al., 2011).
Other effects of tobacco toxins include increased rates of apoptosis
and necrosis in various tissues of the body, as well as increased apop-
tosis in primordial germ cells differentiated from human stem cells in
vitro (Kee et al., 2010). These effects might also manifest as increased
.............................................................................................................................................................................................
Table IV Associations between FSH- and AMH-related SNPs and AFC in African American and Caucasian women.
SNPa Race Gene Allelesb MAF FSH/AMH genotype effect
(concentration)c
AFC genotype effect
(follicles)d
P-valuee
rs6543833 Afr Amer MYADML G/C 0.27 20.62+0.34 (FSH) +1.09+0.32 1.85 × 1023
(9.25 × 1023)*
rs12465811 Afr Amer MYADML T/G 0.32 20.38+0.24 (FSH) +0.94+0.25 1.31 × 1023
(6.55 × 1023)*
rs9875589 Afr Amer TPRXL A/C 0.46 +14.02+3.72 (AMH) +4.88+0.63 3.68 × 1025
(1.84 × 1024)*
rs12295403 Afr Amer TMEM86A T/G 0.10 +16.67+5.11 (AMH) +5.17+0.86 3.34 × 1023
(1.67 × 1022)*
rs11255291 Afr Amer ITIH2 T/C 0.25 21.34+0.22 (FSH) +1.31+0.36 0.211 (1)
rs6488619 Caucasian GRIN2B C/T 0.25 +1.16+0.33 (FSH) +0.55+0.049 0.104 (0.416)
rs10061804 Caucasian NPR3 T/C 0.28 +2.05+0.80 (FSH) +1.44+0.30 0.310 (1)
rs12213875 Caucasian JARID2 A/G 0.37 +13.82+4.18 (AMH) +3.08+0.52 0.0514 (0.206)
rs9396503 Caucasian JARID2 T/G 0.37 +14.92+4.60 (AMH) +3.74+0.66 0.0415 (0.166)
P , 0.05 for four out of five FSH/AMH-associated SNPs also associated with AFC, compared with 0.34 (,1) expected by chance.
aSNPs at each locus are those associated with serum FSH or AMH levels, rather than those with the strongest signal for follicle number.
bAlleles are shown as minor/major allele; bold indicates the effect allele.
cThe difference in mean (+SEM) serum FSH levels (IU/l) or AMH levels (pM) for a given genotype.
dThe difference in mean (+SEM) number of follicles for the corresponding genotype calculated from the regression analysis.
eP-values are based on the Fisher’s exact test for SNP association with the hormone; parentheses denote corrected P-values; *P , 0.05.
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rates of follicular apoptosis or dysfunction within the ovaries. Indeed,
polycyclic aromatic hydrocarbons in cigarette smoke are toxic to
ovarian follicles in both animal models (Essenberg et al., 1951) and
humans (Mattison and Thorgeirsson, 1978). We found that neither
previous nor current smoking was associated with overall lower follicle
counts. However, smoking was associated with an increased extrapo-
lated rate of follicular decline in Caucasian women (P ¼ 0.039). There
was no dose-response between the pack-years of smoking and follicle
number (P. 0.05). Our findings are consistent with the work of Gold
and co-workers, one of the largest, most comprehensive studies on
menopause (Gold et al., 2001). In 14 620 middle-aged women of
the Study of Women’s Health Across the Nation, smoking was asso-
ciated with an earlier age of menopause (0.3–1.2 years earlier) but
there was no dose–response effect of the amount of cigarettes
smoked per day on menopausal age. Similarly, we found no dose–
response of smoking but smoking was positively correlated with an
Figure 5 The association between smoking or oral contraceptive use and several reproductive hormones and follicle counts. Shown are serum
hormone levels or AFCs versus age for women that were current or previous smokers (red points) or non-smokers (black points) (A–F). The
data for all women were fit with a linear regression (gray line) and the regressions for smoking (red line) and non-smoking (black line) women
were compared. P-values indicate a significant change in slope, intercept or both slope and intercept, associated with smoking. There were significant
differences in serum levels of estrone (E1), estradiol (E2) and testosterone (T), and AFC between smoking and non-smoking women (P, 0.05). Also
shown are mean serum levels of testosterone, E1 and AMH in smoking (closed bars) and non-smoking (open bars) women (G) and mean AFCs in oral
contraceptive-using (open bars) and non-using (closed bars) African American and Caucasian women (H) (*P, 0.05).
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increased rate of follicular decline. There was also a positive correl-
ation between female age and number of years of smoking, with
older women on average having smoked for a greater number of
years. Any effects of smoking on the follicle pool therefore, might
be most evident in mid-life.
A slightly later age of menopause has been reported in women that
previously used OCPs (van Noord et al., 1997; Gold et al., 2001),
while other studies have reported no association (Bromberger et al.,
1997; Hardy and Kuh, 1999). It has been hypothesized that OCP
use delays menopause by the hormonal actions of suppressing follicu-
lar recruitment and ovulation, thereby leading to increased numbers of
follicles. In contrast, we found that OCP use did not increase follicle
number. Instead, women who had taken OCPs had similar or slightly
lower follicle numbers compared with women who had never taken
OCPs (P ¼ 0.058 in Caucasians and P ¼ 0.0046 in African Amer-
icans). Similar to previous work on menopause (Gold et al., 2001),
we found no relation between duration of prior OCP use and follicle
number or serum hormone levels. These results suggest that OCP use
is not associated with increased follicle number or alterations in
ovarian reserve hormones. It remains speculative that oral contracep-
tives may actually have some subtle inhibitory effects on follicle
numbers or ovarian reserve in women of reproductive age.
However, as we are limited by sample size, longitudinal studies analyz-
ing these lifestyle factors in larger cohorts of women could provide
further insight on the biological effects of these exposures on the
ovarian reserve. It is likely that complex genetic and environmental
influences affect follicular atresia, as well as the brain-pituitary-ovary
axis and its regulation of gonadotrophins and sex steroid hormones.
Conclusion
This is the first genome-wide study to evaluate genetic associations
with hormone markers of ovarian reserve. We found several differ-
ences between the ovarian reserve phenotypes of Caucasian and
African American women—differences in AMH levels and subtle dif-
ferences in the associations between hormonal markers with age
and follicle number. Smoking and OCP use were associated with
alterations in reproductive hormone profiles and/or follicle number
in both ethnic groups. We identified one variant of marginal genome-
wide significance and several nominally-significant variants associated
with FSH levels in African American women, as well as nominal var-
iants associated with FSH and AMH levels in both ethnic groups.
These variants were validated in the Caucasian cohort. Several of
the variants were also significantly associated with follicle number.
Interestingly, none of the associated genes have previously demon-
strated roles in ovarian function and now represent a group of candi-
date genes for further investigation. Future studies including multi-site
meta-analyses on additional larger cohorts of women and replication
in independent studies are needed. Fine mapping or sequencing and
functional in vitro gene expression and gain- and loss-of-function
studies on the identified candidate genes might reveal any effects of
the genetic variants and the putative functions of these genes. Longi-
tudinal studies are also needed to explore the effect of these variants
and genes on the decline in ovarian reserve with age.
A better understanding of the genes and environmental factors that
impact ovarian reserve may provide greater insight on the process of
reproductive aging, the genetic requirements of human fertility and risk
for development of disease. It is hoped that this work may help form a
foundation for genetically identifying women at risk for early ovarian
failure, fertility defects and hence associated reproductive and
somatic diseases.
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